Tempus  

A partner in precision oncology from early to late-stage cancers, our comprehensive platform enables seamless testing along the patient journey to help guide your management decisions

Broad CGP testing: Combined DNA + RNA whole transcriptome sequencing to maximize alteration detection for treatment and clinical trial match. 

Somatic and germline testing: Suite of testing solutions to inform personalized management options available on a single platform.

Solid Tumor + Normal Match DNA sequencing: Reduction in somatic false positive calls compared to tumor-only analysis and detection of potential germline findings in a limited set of genes. 

Complementary solid tumor and liquid biopsy NGS: Flexible ordering options utilizing a dual testing approach or automatic conversion in the event of insufficient tissue to ensure biomarker results are delivered without delay. 

Optional add-on algorithmic tests: Advanced patient information without the need for additional tissue.

Smart reports: Integrated molecular and clinical results that inform comprehensive and actionable precision medicine strategies.

Tempus One: AI-enabled clinical assistant that seamlessly integrates into your workflow to help you access patient information quickly.

Connectivity: Industry leader in supporting health systems with integrating structured somatic variant results into the EMR.

Tempus provides an integrated suite of solutions to help focus, accelerate, and de-risk clinical drug development. 

Data Collaborations: Access DNA, RNA, H&E images, and other clinical, imaging, and molecular data to uncover new insights across the R&D continuum.

Cloud-native Analytics Platform: Tempus Lens enables fast identification of fit-for-purpose patient populations across hundreds of petabytes of data, with pre-built visualizations and cloud-based coding environments designed to surface actionable insights in minutes.

Biological Modeling: Tumor organoid drug screening services to generate multimodal data insights (phenotypic, molecular, clinical) for preclinical research.

Next-Generation Sequencing and CDx: Solid tissue, liquid biopsy, DNA, whole transcriptome RNA, MRD detection for research and CDx development.

Full-service CRO: Compass is optimized for biopharma and complex drug development in oncology.

Clinical Trials Network: Tempus TIME enables rapid patient identification and just-in-time site activation through a powerful integration of data, technology, and streamlined operations.

Prospective Evidence Generation: Tempus Studies delivers agile, prospective datasets which can include longitudinal genomic, transcriptomic, imaging, and clinical data. 

AI-enabled Care Pathway Intelligence Platform: Tempus Next accelerates the adoption of evidence based care and increases adherence to clinical guidelines.

AI Algorithm Development and Deployment: Generate clinical insights without the need for an additional specimen through DNA, RNA, H&E images, or other health data.